AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05439083 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccine
Description: All participants will receive the immunization schedule according to guidelines: immunosuppressed patients will receive a three-dose schedule: 0.5 mL intramuscular injection of 9vHPV at entry plus an additional dose at month 2 and month 6. Healthy controls aged 9-14 years will receive a two-dose schedule: 0 and 6 months.
Study NCT06359639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring
Description: Five 50-60-minute videoconferencing sessions of cognitive restructuring based on Mind Over Mood: Second Edition (MOM2) (Greenberger \& Padesky, 2016) and The Clinician's Guide to CBT Using MOM2 (Padesky \& Greenberger, 2019) as guides. The sessions will consist of understanding the cognitive model, filling in Thought Records, and complementary coping strategies of looking for evidence, action planning, and acceptance.
Study NCT06359639 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive counselling
Description: Five 50-60-minute videoconferencing sessions of supportive counselling consisting of psychoeducation on breakup effects, validation of breakup experiences and emotions, introduction to deep breathing and progressive muscle relaxation, and identification of existing coping strategies.
Study NCT04283604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPH
Description: The treatment will include taking the patient's own medication by the patient himself in the treatment session 60-180 minutes before the beginning of the tests, according to their prescription given by their own physician. Participants must have consumed this medication at least 3 months before the first session as their regular treatment for ADHD. Note, we are not planning on giving the medication to the participant, rather he/she will consume their own prescribed MPH by them self.
Study NCT05360485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOV'D (Move Often eVery Day)
Description: The MOV'D intervention is a remotely-delivered, peer-supported intervention that delivers exercise snack (2-5 minutes of moderate to vigorous activity) and behavior change technique (BCT) videos to a private social media support group with the goal of interrupting prolonged sitting at work with MVPA minutes.
Study NCT05360485 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Self-Monitoring
Description: All participants receive a Fitbit and are told to monitor their physical activity for the duration of the study period.
Study NCT05360485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit Self-Monitoring
Description: All participants receive a Fitbit and are told to monitor their physical activity for the duration of the study period.
Study NCT06626295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise-snack group
Description: Adolescents in the exercise-snacks group will perform 4 \&amp;amp;amp;#34;exercise-snacks\&amp;amp;amp;#34; sessions per day during 3 weeks in addition to multidimensional care program. These sessions will consist of 1-min various intense supervised exercises . They will also receive information about their attitudes to physical activity.
Study NCT05326581 — intervention group
Intervention type: DEVICE
Intervention: mri
Description: The people included will carry out an MRI comprising the sequence currently used in routine care and the different variants of the sequence being tested, for the optimization of the parameters. The duration of the examination (or the extension of the examination planned as part of patient care) will be from a few minutes to an hour depending on the sequences to be optimized. Subjects who agree to research for more than 30 minutes in the MRI machine will be compensated with a multi-brand gift voucher worth 30 euros.
Study NCT04481802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RadiaAce gel
Description: Patients will apply the RadiaAce to the treatment area starting 5 days before radiation treatment. The Hydrogel/cream will be applied three times a day with a minimum of four hours between applications. Treatments will be used through the course of RT and for 6 days after the last fraction of radiation.
Study NCT04481802 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biafine
Description: Patients will apply the Biafine to the treatment area starting 5 days before radiation treatment. The Hydrogel/cream will be applied three times a day with a minimum of four hours between applications. Treatments will be used through the course of RT and for 6 days after the last fraction of radiation.
Study NCT06148311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: One matching placebo will be given under the tongue on a thin dissolvable film.
Study NCT06148311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 120 mcg will be given under the tongue on a thin dissolvable film.
Study NCT05287529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Via Telehealth - Immediately
Description: The yoga program is an in-home, chair-assisted yoga class focused on balance. Each class will be led by a certified yoga teacher who has completed training the the yoga for Seniors Program. Classes will consist of no more than 12 participants. Each class will be attended by a local community member who will facilitate community building before and after class and will be available to activate local emergency medical services in the unlikely event that the need arises. Classes are 75 minutes in duration and meet two times per week.
Study NCT05287529 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga Via Telehealth - Waitlisted
Description: The yoga program is an in-home, chair-assisted yoga class focused on balance. Each class will be led by a certified yoga teacher who has completed training the the yoga for Seniors Program. Classes will consist of no more than 12 participants. Each class will be attended by a local community member who will facilitate community building before and after class and will be available to activate local emergency medical services in the unlikely event that the need arises. Classes are 75 minutes in duration and meet two times per week.
Study NCT06619626 — intervention group
Intervention type: DEVICE
Intervention: alveolar recruitment strategy applied group
Description: the effect of alveolar recruitment strategy on the mechanical parameters of the patients
Study NCT06619626 — intervention group
Intervention type: DRUG
Intervention: group without alveolar recruitment strategy
Description: effect on mechanical parameters of patients without alveolar recruitment strategy
Study NCT05325216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POPRC+OIN
Description: Pelvic-organ preserving radical cystectomy with orthotopic ileal neobladder
Study NCT05325216 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRC+OIN
Description: Standard radical cystectomy with orthotopic ileal neobladder
Study NCT06385093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eldecalcitol capsules
Description: Oral eldecalcitol 0.75μg daily
Study NCT06385093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfacalcidol tablets
Description: Oral Alfacalcidol 0.5μg daily
Study NCT06385093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate tablets
Description: 1.5g Calcium carbonate daily
Study NCT04819230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification
Description: A four-week computerized attentional and interpretive bias modification protocol in which participants complete both ATT and ITT tasks twice per week, totaling to eight experimental sessions (see experimental arm for more detail.)
Study NCT04819230 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Bias Control
Description: A four-week computerized attentional and interpretive stimuli protocol in which participants complete both ATT-C and ITT-C tasks twice per week, totaling to eight control sessions (see placebo control arm for more detail.)
Study NCT06344910 — intervention group
Intervention type: OTHER
Intervention: Best practice alert for the notification of patients with HFrEF and recommended evidence-based therapies
Description: An algorithm will check if the patients if the patient has an age >18 year and is treated at the cardiology department for HFrEF. The use of GDMT is determined using prescriptions data electronic health records (EHR). If the patient does not receive treatment for all 4 drug classes (ACE/ARB/ARNi, beta-blocker, MRA, SGLT2-inhibitor), an electronic alert will be displayed suggesting the clinician to prescribe additional medication when clinically indicated, including relevant recent laboratory results (renal function and electrolytes) and other relevant measures (LVEF, blood pressure and heart rate). The alert is linked to an order set to aid in the prescription of GDMT according to current guidelines.~Results will compared to a retrospective cohort (t=-12 to t=-6) months, and a silent mode cohort (t=-6 to t=0 months, in which a paired and a before and after analysis will be performed to evaluate the effect of the alert.
Study NCT06426368 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ST2
Description: ELISA used to detect levels of ST2 and BNP as inflammatory biomarkers in patients with heart failure
Study NCT05489627 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medial Collateral Ligament Reconstruction With Anteromedial Reinforcement
Description: Medial knee instabilities will be addressed in this arm as described in the published technique: K. Malinowski, K. Hermanowicz, A. Góralczyk, R.F. LaPrade, Medial Collateral Ligament Reconstruction With Anteromedial Reinforcement for Medial and Anteromedial Rotatory Instability of the Knee, Arthrosc. Tech. 8 (2019) e807-e814. https://doi.org/10.1016/j.eats.2019.03.019.~Due to the fact that isolated injury of medial stabilizers of the knees is very rare, included will be patients with concomitant ACL QTB reconstruction and abovedescribed MCL reconstruction. Any accompanying intraarticular injuries such as meniscal lesions will be addressed as well.
Study NCT04688827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: 15 weeks of resistance training (additional to endurance training)
Study NCT05532072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Rapamycin plus Methylprednisolone
Study NCT05532072 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methylprednisolone
Description: Methylprednisolone Alone
Study NCT05532072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone Alone
Study NCT06136754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varnishes, Fluoride
Description: Fluoride varnish containing 5.0% NaF
Study NCT06136754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varnishes, Fluoride
Description: Fluoride varnish containing 5.0% NaF
Study NCT05890131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital letter
Description: A digital letter with evidence-based information about the newly approved heart failure therapy option, SGLT-2 inhibitors. The letter will also invite recipients to be evaluated by a heart failure specialist for potential initiation of the therapy.
Study NCT06778902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacytidine
Description: Azacytidine: 75mg/m2, d1-d5
Study NCT06778902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-GemOx
Description: Rituximab: 375mg/m2, d6; Gemcitabine: 1g/m2, d7 Oxaliplatin: 100mg/m2, d7
Study NCT05331703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: designed physical therapy program in addition to program of virtual reality.
Description: physical therapy program in addition to program of virtual reality.
Study NCT05331703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: designed physical therapy program in addition to program of mirror therapy.
Description: physical therapy program in addition to program of mirror therapy.
Study NCT04976218 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TGFβR-KO CAR-EGFR T Cells
Description: Enrolled patients will be administered TGFβR-KO CAR-EGFR T Cells in 3+3 based escalation manner. The infused CAR+ T cell dose in phase IA will be started initially at 1-2×10\^5/kg, dose 2 will be 1×10\^6/kg，and dose 3 will be 1×10\^7/kg, if DLT occurs in dose level 3, the following dose will return to 5×10\^6/kg. In expansion period, the dose of infused CAR+ T cells will be determined by the recommended cell dose from phase IA.
Study NCT05785507 — intervention group
Intervention type: OTHER
Intervention: PriskA tool
Description: PriskA tool is an algorithm that generates a risk score of having PCOS.
Study NCT05732961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Participants will be treated with Luspatercept, with a starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle)
Study NCT04027270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical therapy 1-2 times per week for 3 months postoperatively to include lifestyle education, manual therapy, and exercise.
Study NCT06491290 — intervention group
Intervention type: OTHER
Intervention: No intervention administered
Description: NA (not applicable)
Study NCT05123703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab 300 milligrams (mg) will be administered by IV infusion to participants who weigh \< 35 kilograms (kg) and ocrelizumab 600 mg IV will be administered to participants who weigh ≥ 35 kg on Days 1 and 15 (half the dose, 2 weeks apart) and Q24W thereafter.
Study NCT05123703 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab Placebo
Description: Ocrelizumab matching placebo will be administered by IV infusion on Day 1 and Day 15 and Q24W thereafter.
Study NCT05123703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fingolimod
Description: Fingolimod will be administered daily as a capsule per the prescribing information (0.25 mg to participants who weigh ≤ 40 kg and 0.5 mg to participants who weigh > 40 kg).
Study NCT05123703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fingolimod Placebo
Description: Fingolimod matching placebo will be administered daily as a capsule.
Study NCT04704427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive BCI training
Description: In the experimental group, the participants receive non-invasive rehabilitative BCI training. The training using the lower limb orthosis targeted the patient's ability to walk.
Study NCT04704427 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physiotherapy protocol
Description: In the control group，the participants receive the traditional physiotherapy protocol, including muscle strength training, balance training and walking training, etc.
Study NCT05922072 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric aspiration for measurement of Residual Gastric Volume
Description: The patients enrolled in this study undergoing elective general anesthesia,their mean gastric residual volume will be measured by taking Nasogastric tube aspirate.
Study NCT05922072 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasogastric aspiration for measurement of Residual Gastric Volume
Description: The patients enrolled in this study undergoing elective general anesthesia,their mean gastric residual volume will be measured by taking Nasogastric tube aspirate.
Study NCT05922072 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Aspiration for Measurement of Gastric pH
Description: The patients enrolled in this study undergoing elective general anesthesia,their mean gastric gastric PH will be measured by taking Nasogastric tube aspirate.
Study NCT05922072 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasogastric Aspiration for Measurement of Gastric pH
Description: The patients enrolled in this study undergoing elective general anesthesia,their mean gastric gastric PH will be measured by taking Nasogastric tube aspirate.
Study NCT06325293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin Pfizer®
Description: Azithromycin Pfizer® powder for oral suspension will be used in the active comparator arm: 1 daily dose for 5 days, 10mg/kg/day on day 1 and 5mg/kg/day on days 2-5
Study NCT06325293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control comparator arm: 5 days of placebo
Study NCT06242639 — intervention group
Intervention type: OTHER
Intervention: Clinical examination
Description: clinic and radiographic evaluation
Study NCT06074133 — intervention group
Intervention type: PROCEDURE
Intervention: Blood collection
Description: Undergo blood draw
Study NCT06080646 — intervention group
Intervention type: OTHER
Intervention: cross-sectional MRI and EEG assessments (NO INTERVENTION)
Description: n/a there is no intervention in this observational study
Study NCT06778564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD 100 mg/mL Oral Solution
Description: Daily dose 1000mg, taken as 500mg (5ml) b.i.d for 6 weeks. For participants with a weight lower than 50 kg, the dose is to be adjusted to 20 mg/kg/day divided over 2 intakes of 10 mg/kg/day, for a period of 6 weeks
Study NCT06778564 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5ml b.i.d for 6 weeks; For participants with a weight lower than 50 kg, the dose is to be adjusted to 20 mg/kg/day divided over 2 intakes of 10 mg/kg/day, for a period of 6 weeks
Study NCT06074133 — intervention group
Intervention type: PROCEDURE
Intervention: Chest Computed Tomography
Description: Undergo standard of care chest Computed Tomography
Study NCT05061654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane-tazobactam IV
Description: Empiric Ceftolozane-tazobactam IV 3g over 1 hour every 8 hours. The dose will be reduced to 1.5g 8 hourly in patients with CrCl of 30-50 ml/min, and to 750mg every 8 hours in those with CrCl of 15-29 ml/min. Patients on hemodialysis will receive 2.25g loading dose followed by 450mg every 8 hours.
Study NCT04502394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth
Study NCT04902651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HM242-Gel
Description: HM242-Gel compared to Intrasite Gel in patients with a venous leg ulcer
Study NCT04902651 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrasite Gel
Description: HM242-Gel compared to Intrasite Gel in patients with a venous leg ulcer
Study NCT04919460 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: clinical observation combined with pathological biopsy
Description: Inspecting and palpating the oral cavity and neck of the screened object. If positive lesions are found, then further pathological biopsy will be performed.
Study NCT04919460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical observation, in vivo staining (reagent: toluidine blue) combined with pathological biopsy
Description: (2) Inspecting and palpating the oral cavity and neck of the screened object. At the same time, in vivo staining is performed on each participant. The reagent used for staining is toluidine blue. As long as the screening subjects found positive lesions or abnormal living body staining, pathological biopsy was performed.
Study NCT06477679 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: • Furlow with buccinators myomucosal flap
Description: • Furlow with buccinators myomucosal flap. Two opposing Z-plasties were designed on the oral and nasal mucosal surface. The posterior based flap on each surface was composed of muscle and mucosa, and the anterior surface was composed of mucosa only. BMFs were raised from the donor site, and immediately transferred to the recipient site to repair the defect. The flaps were sutured to the recipient site. The donor site was also closed primarily
Study NCT06477679 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: • Two flap palatoplasty as von langenbeck technique
Description: • Two flap palatoplasty as von langenbeck technique, Upper left: Medial incisions design. Upper right: Lateral relaxing incisions and nasal mucosa closure using the anterior triangular flap and lateral nasal mucosa flaps. Release of the abnormal muscular insertion is performed. But two flap palatoplasty can lengthen the soft palate by push-back
Study NCT05137600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-2173
Description: ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth
Study NCT05137600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam is a sensitive CYP3A index substrate
Study NCT05137600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin is a sensitive P-gp index inhibitor to evaluate potential effect of P-gp inhibition on ATI-2173 and its metabolites(clarithromycin)
Study NCT06455306 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Air-polishing with erythritol at different time points
Description: The air-polishing device will be inserted into each site of the peri-implant pocket at an angle ranging from 60 to 90 degrees, and each surface will be debrided for 5 seconds using erythritol powder (AIRFLOW Powder PERIO; EMS). In this group this procedure will be done ate baseline, 1 month and 2 months